Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the logistics of study conduct. By leveraging the expertise of their vendors, sponsors and contract research organizations (CROs) can avoid common pitfalls that can contribute to inefficiencies, safety concerns, and increased costs.
Read the Drug Discovery World article by Stephanie Larimer, Q2 Solutions, Decentralized Trials Solutions Manager and Tom Brazier, mdgroup, Decentralized Clinical Solutions Director, as they shared their insights and opportunities for decentralized clinical trials and how common pitfalls can be avoided through communications and streamlined working.
Read the article
Recently expanded to nearly 165,000-square-feet, our state-of-the-art laboratory is equipped with a broad spectrum of enhanced scientific solutions for genomics, flow cytometry, translational science...
Speaker - Oswaldo A Lozoya, PhD, Genomics Staff Scientist - TSAIL, Q2 Solutions As part of the Machine Learning and Single Cell Genomics in Public Health session, Oswaldo presents insights,...
Biotech companies are powering the pharmaceutical pipeline by driving innovation to address unmet medical needs. Navigating a rapidly changing and increasing complex landscape takes expertise and...